Litcius/Paper detail

Involvement of HSP90 in ischemic postconditioning-induced cardioprotection by inhibition of the complement system, JNK and inflammation

Dongxiao Wang, Zheng Huang, Qing‐Jie Li, Guo-Qiang Zhong, Yan He, Weiqiang Huang, Xiaoli Cao, Ronghui Tu, Jian‐Jun Meng

2020Acta Cirúrgica Brasileira26 citationsDOIOpen Access PDF

Abstract

PURPOSE: To investigate whether heat shock protein 90 (HSP90) is involved in complement regulation in ischemic postconditioning (IPC). METHODS: The left coronary artery of rats underwent 30 min of occlusion, followed by 120 min of reperfusion and treatment with IPC via 3 cycles of 30s reperfusion and 30s occlusion. The rats were injected intraperitoneally with 1 mg/kg HSP90 inhibitor geldanamycin (GA) after anesthesia. Eighty rats were randomly divided into four groups: sham, ischemia-reperfusion (I/R), IPC and IPC + GA. Myocardial infarct size, apoptosis index and the expression of HSP90, C3, C5a, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1β and c-Jun N-terminal kinase (JNK) were assessed. RESULTS: Compared with the I/R injury, the IPC treatment significantly reduced infarct size, release of troponin T, creatine kinase-MB, and lactate dehydrogenase, and cardiomyocyte apoptosis. These beneficial effects were accompanied by a decrease in TNF-α, IL-1β, C3, C5a and JNK expression levels. However, all these effects were abrogated by administration of the HSP90 inhibitor GA. CONCLUSION: HSP90 exerts a profound effect on IPC cardioprotection, and may be linked to the inhibition of the complement system and JNK, ultimately attenuating I/R-induced myocardial injury and apoptosis.

Topics & Concepts

CardioprotectionMedicineCreatine kinaseGeldanamycinLactate dehydrogenaseHsp90IschemiaApoptosisTumor necrosis factor alphaHeat shock proteinReperfusion injuryPharmacologyInternal medicineAnesthesiaChemistryEnzymeBiochemistryGeneComplement system in diseasesCardiac Ischemia and ReperfusionOrgan Transplantation Techniques and Outcomes